|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cervical Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Uterine Cervical Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Urogenital Neoplasms | |||||
| Uterine Cervical Diseases | |||||
| Uterine Diseases | |||||
| Uterine Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Papanicolaou test | |||||
| colposcopic biopsy | |||||
| fluorescent antibody technique | |||||
| study of high risk factors | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antibodies | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| Robert H. Lurie Cancer Center | |||||
| National Cancer Institute (NCI) | |||||